Sign Out
The safety of COMBIVENT during human pregnancy is not established. The usual precautions regarding the use of drugs in pregnancy, especially during the first trimester, should be observed. The inhibitory effect of COMBIVENT on uterine contraction should be taken into account.
Salbutamol sulphate and ipratropium bromide are probably excreted in breast milk and their effects on the neonate are not known. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that ipratropium bromide would reach the infant to an important extent, especially when taken by inhalation. However, because many drugs are excreted in breast milk, caution should be exercised when COMBIVENT is administered to a nursing woman.
